CD19 and B-cell chronic lymphocytic leukemia: Furthermore allograft settings were introduced to improve the CLL engraftment by adding allogeneic CD34+ cord blood cells and antigen presenting allogeneic CD14+ monocytes or CD19+ B cells, with the consequence of unforeseeable immunological changes in CLL biology [27].